Has Aerie Put The 'Binary Boogeyman' To Bed With Roclatan Phase III Data?

Published: May 26, 2017

Aerie Pharmaceuticals Inc (NASDAQ: AERI) shares were seen up over 29 percent Thursday after the company reported positive Phase III trial data on its glaucoma treatment candidate, Roclatan. According to the company, Roclatan achieved the primary efficacy endpoint in demonstrating superiority over both latanoprost and Rhopressa.

Back to news